Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Filings indexed 293 across all filing types
Latest filing 2023-06-28 Director's Dealing
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-06-28 English
Director's Dealing 2023
Director's Dealing
2023-06-28 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 22, 2023, by Acrivon Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at the 2023 annual meeting, including election results for directors and ratification of the independent auditor. The document provides detailed voting results for each proposal. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4255 characters, which is not extremely short, and it contains substantive voting data, not just an announcement of a report. Therefore, it is not a Report Publication Announcement or Regulatory Filing. It is not an Annual Report, Earnings Release, or Management Report. The focus is on shareholder voting results at the Annual Meeting. Hence, the correct classification is DVA with high confidence.
2023-06-22 English
Director's Dealing 2023
Director's Dealing
2023-06-20 English
Director's Dealing 2023
Director's Dealing
2023-06-20 English
Director's Dealing 2023
Director's Dealing
2023-06-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.